Background {#Sec1}
==========

Breast cancer, the most common cancer in women, annually affects 1.8 million women worldwide \[[@CR1]\]. Approximately 12% of women in the United States are estimated to receive diagnoses of breast cancer in their lifetime \[[@CR2]\]. Breast cancer is classified into three subtypes according to the expression of receptors: hormone (estrogen and progesterone)-receptor-positive breast cancer, human epidermal growth factor receptor 2 (HER2)-positive breast cancer, and triple-negative breast cancer (TNBC; lacking hormone receptors as well as HER2) \[[@CR3]\]. Patients with TNBC exhibit a high risk of early tumor recurrence and poor prognosis \[[@CR4]\]. Chemotherapy is a principal treatment for breast cancer, but resistance to chemotherapy---occurring in at least a quarter of all cases---is a major problem in breast cancer management, causing treatment failure in more than 90% of patients with metastatic cancers \[[@CR5]--[@CR8]\]. The mechanisms underlying resistance in different breast cancer subtypes are diverse, complex, and unclear. Cancer cells may develop resistance to a specific class of cytotoxic drugs owing to changes in target proteins and in cellular biological activities affecting the efficacy of the drugs. The changes include increased repair of DNA damage and decreased apoptosis, membrane permeability, and drug metabolism. Furthermore, the uptake of water-soluble drugs decreases due to a decrease in the expression of transporter proteins responsible for drugs to enter the cells and the energy-dependent efflux of hydrophobic drugs increases, for instance, through increased expression of adenosine triphosphate (ATP)-binding cassette (ABC) transporter proteins \[[@CR9]--[@CR15]\].

Doxorubicin, an anthracycline antibiotic, has been considered one of the most effective agents in breast cancer treatment since the 1970s \[[@CR16]\]. Doxorubicin mainly intercalates between DNA bases and subsequently inhibits topoisomerase II activity, thus impairing DNA synthesis \[[@CR17]\]. Doxorubicin also generates free radicals, which damage DNA and cell membranes \[[@CR18]\]. Doxorubicin enters the cells through passive diffusion and accumulates intracellularly, particularly in the nuclear compartments \[[@CR19]\]. However, doxorubicin is nonselective toward cancer cells; thus, it causes toxicity in the heart, brain, liver, and kidneys \[[@CR19], [@CR20]\]. The most prominent adverse event is life-threatening cardiotoxicity, which limits the prescribed dose of doxorubicin \[[@CR20]\]. Doxorubicin resistance is another crucial cause of treatment failure \[[@CR3]\]. The reported response rates to doxorubicin as a single agent for breast cancer treatment were 43% and 28% in patients who were exposed to doxorubicin for the first time and those who had been exposed to the drug for more than once, respectively. Thus, nearly 50% of the treated patients developed resistance to doxorubicin, making resistance the major cause of treatment failure \[[@CR21]\]. The predominant mechanism underlying resistance to doxorubicin in breast cancer cells is the overexpression of a few ABC transporter proteins that increase doxorubicin efflux, thus decreasing intracellular drug concentrations \[[@CR3], [@CR9], [@CR22]\]. Other mechanisms underlying doxorubicin resistance include alterations in cellular signaling pathways, leading to failure of apoptosis, and changes in gene expression, resulting in a chemoresistant phenotype \[[@CR3], [@CR19]\].

Increased expression of ABC transporter proteins has been correlated with poor clinical prognosis in patients with breast cancer of any subtype \[[@CR23], [@CR24]\]. The human genome has 49 members of the ABC transporter family, divided into seven subfamilies (ABCA--ABCG) based on their sequence similarities \[[@CR25]\]. These membrane proteins actively pump various structurally and functionally diverse amphipathic anticancer drugs from inside the tumor cells to the outside, thereby decreasing intracellular drug concentrations and causing chemotherapeutic drug resistance \[[@CR9], [@CR10]\]. The primary members of the ABC transporter family leading to doxorubicin resistance in cancer cells are the ABCBs, the ABCCs \[also known as multidrug resistance (MDR)-associated proteins\], and ABCG2 (also known as breast cancer resistance protein, mitoxantrone resistance protein, or placenta-specific ABC transporter) \[[@CR9], [@CR26], [@CR27]\]. Among the aforementioned ABC transporter proteins, ABCB1 \[a P-glycoprotein, (p-gp)\], ABCC1, and ABCG2 have been extensively characterized in breast cancers \[[@CR23], [@CR24], [@CR28], [@CR29]\]. Inhibitors of the ABC transporter proteins activity were used to overcome ABC transporter-mediated MDR for obstructing the expression of the transporter proteins or inhibiting their function. For example, a combination of doxorubicin and verapamil, a P-gp inhibitor, can reverse the resistance of breast cancer cells to doxorubicin \[[@CR30]\]. However, verapamil can potentiate the cardiotoxicity of doxorubicin \[[@CR31]\]. Over the past decades, numerous inhibitors of MDR-related ABC transporter proteins have been developed and identified. However, the development of most inhibitors has been discontinued because of their low binding affinity, toxicity, detrimental pharmacokinetic interactions, and low patient survival advantages \[[@CR9], [@CR32]\]. Furthermore, the expression patterns of ABC transporter proteins in breast cancer cells are heterogeneous; thus, the efficacy of inhibitors specific to some ABC transporter proteins is low \[[@CR33]\].

Sulbactam, a β-lactamase inhibitor belonging to Ambler class A, is administered along with β-lactam antibiotics (e.g., ampicillin and penicillin) to prevent the hydrolysis of the antibiotics by bacterial β-lactamases. Sulbactam inhibits the activity of β-lactamases by irreversibly binding to their active sites. The β-lactam/β-lactamase inhibitor combination has been approved by the US Food and Drug Administration for treating dermatological, gynecological, and intraabdominal infections \[[@CR34]\]. Although sulbactam has relatively low intrinsic biological activity, it has inherent activity against some bacterial species, including *Neisseria gonorrhoeae*, *Bacteroides fragilis*, and *Acinetobacter* spp. \[[@CR35], [@CR36]\]. Preliminary in vitro experiments have demonstrated that sulbactam kills bacteria by binding to the penicillin-binding proteins (PBPs) of *Acinetobacter* spp. and downregulating the expression of PBP1 and PBP3 \[[@CR35], [@CR37]\]. Furthermore, sulbactam reduces the expression of the ABC transporter proteins in *Acinetobacter baumannii* \[[@CR38]\]. The ABC transporter superfamilies are highly conserved protein families, and their structural features and mechanisms of action have been conserved from prokaryotes to humans \[[@CR39], [@CR40]\]. Thus, we hypothesized that if sulbactam can reduce the expression of ABC transporter proteins in breast cancer cells, then it can reduce the efflux of doxorubicin from breast cancer cells and enhance its efficacy.

Materials and methods {#Sec2}
=====================

Reagents {#Sec3}
--------

Doxorubicin hydrochloride was purchased from Sigma-Aldrich (St. Louis, MO, USA). Sulbactum sodium was obtained from TTY Biopharm (Taiwan). Verapamil was obtained from Orion Pharma (Espoo, Finland).

Cell lines and cell culture {#Sec4}
---------------------------

The breast carcinoma cell lines MDA-MB-231, MDA-MB-435, MDA-MB-453, and MDA-MB-468 were maintained in Dulbecco's modified Eagle's medium (DMEM) (Hyclone, Thermo Fisher Scientific Inc. Waltham, MA, USA) containing 10% fetal bovine serum (FBS; Gibco-BRL, Rockville, MD, USA) and 100 units/mL penicillin--streptomycin (Gibco-BRL). The breast carcinoma cell lines MCF-7, BT474, and T-47D were maintained in Roswell Park Memorial Institute (RPMI)-1640 medium (Hyclone) containing 10% FBS and 100 units/mL penicillin--streptomycin. The human breast epithelial cell line MCF-10A was maintained in DMEM/F12 medium containing 5% horse serum (Invitrogen, Carlsbad, CA, USA), 20 ng/mL epithelial growth factor (Peprotech, Rocky Hill, NJ, USA), 0.5 μg/mL hydrocortisone (Sigma-Aldrich), 10 μg/mL insulin (Sigma-Aldrich), and 100 units/mL penicillin--streptomycin. All cell lines were incubated at 37 °C and 5% CO~2~.

MTT assay {#Sec5}
---------

The MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) assay was used to access cytotoxicity. The cells were grown in 96-well plates at a density of 1.5 × 10^4^ cells/well. To determine the toxicities of sulbactam and doxorubicin, sulbactam and doxorubicin were added at various concentrations into the wells. At 48 h after treatment, the medium in the wells was replaced with 100 µL/well of medium containing 0.5 µg/µL MTT and incubated for 4 h. Subsequently, the medium was removed and 100 µL DMSO was added in each well to dissolve the formazan crystals. The absorbance of the samples was measured at 550 and 655 nm as the test and reference wavelengths, respectively, by using an iMark microplate reader (Bio-Rad, Hercules, CA, USA). To determine the effects of the combination of sulbactam and doxorubicin, various concentrations of doxorubicin were added to the medium containing 2 mM sulbactam in 96-well plates seeded with the breast cancer cells. The MTT assay was performed as described above. The cytotoxicity was expressed as relative viability (percentage of control). The percentage of cell survival in the negative control (without sulbactam and doxorubicin treatment) was considered 100. Relative viability = \[(experimental absorbance − background absorbance)/(absorbance of untreated control − background absorbance)\] × 100%. The half maximal inhibitory concentration (IC~50~) values of sulbactam, doxorubicin, and the combinations of sulbactam and doxorubicin were calculated using the survival curves by using the Bliss method. The degree of resistance was calculated by determining the ratio of the IC~50~ of the cells treated with sulbactam--doxorubicin combinations to that of the cells treated with doxorubicin alone.

Real-time RT-PCR {#Sec6}
----------------

Total RNA was extracted using TriZol (Invitrogen) and reverse transcribed (SuperScript III reverse transcriptase, Invitrogen and ExcelRT Reverse Transcriptase RP1000, SMOBIO, Taiwan). Real-time reverse transcription polymerase chain reaction (Real-time RT-PCR) was performed on ABI StepOnePlus™ Real-Time system using the SYBR Green PCR Master Mix (Applied Biosystems). The sequences of the PCR primers were listed in Table [1](#Tab1){ref-type="table"}. The condition for PCR was 95 °C for 10 min, followed by 40 rounds of 95 °C for 15 s and 60 °C for 1 min. The data were analyzed by StepOne Software v2.2.2.Table 1List of primers of ABC transporters used for real-time RT-PCRGeneRefSeqForward oligo sequenceReverse oligo sequenceABCB1NM_000927AGCTCGTGCCCTTGTTAGACAGTCCAGGGCTTCTTGGACAAABCB5NM_178559CACAAAAGGCCATTCAGGCTGCTGAGGAATCCACCCAATCTABCB8NM_007188CATCGCCTTCAACTGCATGGGACCTTTGCACTGTCTGGGAABCB10NM_012089TGCGGTTGGATTTCTCACGACACACAGAAACACGGCACTGABCC1NM_004996CGCTCTGGGACTGGAATGTAGGTAAAAACAAGGCACCCAABCC2NM_000392TGCACAAGCAACTGCTGAACCCTCTGGCCTATGCTCAGGTTABCC3NM_020038ACCCAGTTTGATACCTGCACTGTGGACCCTGGTGTAGTCCATGAABCC4NM_005845TTGGACACGGTAACTGTTGCAGGAATGTCGGTTAGAGGTTTGGABCC5NM_005688ATTTGGACCCCTTCAACCAGTACGGTAGCTGAGCAATACATTCTTTCATABCC10NM_033450CCTGTTGTTGGTGCTCTTCCGGCCCTGTCCTTATGTAGGCABCG2NM_004827TATAGCTCAGATCATTGTCACAGTCGTTGGTCGTCAGGAAGAAGAGGAPDHNM_002046CCACCCATGGCAAATTCCTCGCTCCTGGAAGATGGTG

Efflux assay of doxorubicin {#Sec7}
---------------------------

The MDA-MB-453 and MDA-MB-468 cells were seeded on coverslips in 12-well plates at a concentration of 1 × 10^5^ cells/well and grown for 16 h. On the following day, the cells were washed with phosphate buffered saline (PBS) and incubated with 2 mM sulbactam or 5 µM verapamil for 30 min before treating them with 2 µM doxorubicin for 2 h. The cells were subsequently incubated in a doxorubicin-free medium for 0, 8, 12, and 16 h. Images were obtained using a LSM 780 confocal microscope (Zeiss) and analyzed using ZEN 2012.

Gel electrophoresis {#Sec8}
-------------------

The equivalence of the human cell lines was analyzed through 12.5% sodium dodecyl sulfate--polyacrylamide gel electrophoresis (SDS-PAGE). The gels were then stained using the VisPRO protein stain kit (Visual Protein Biotech, Taiwan) for 5 min. After staining, the gels were washed with Milli-Q water and stored at 4 °C until in-gel digestion.

In-gel digestion {#Sec9}
----------------

The gel lanes corresponding to the samples were cut into five slices, and each slice was subjected to in-gel digestion according to the method of Shevchenko \[[@CR41]\]. Briefly, the slices were washed thrice with 50 mM ammonium bicarbonate (pH 7.9) and dehydrated using 50 mM AMBC + 50% acetonitrile (ACN). Subsequently, the cysteine bonds were reduced after treatment with 10 mM dithiothreitol for 1 h at 56 °C and alkylated using 50 mM 4-vinylpyridine for 45 min at room temperature in the dark. After two subsequent wash--dehydration cycles, the slices were dried for 10 min in a vacuum centrifuge (ThermoFisher, Breda, Netherlands) and incubated overnight with 6.25 ng/μL trypsin in 50 mM AMBC at 25 °C. The resulting peptides were extracted once in 100 μL of 1% formic acid and then two times in 100 μL of 50% ACN in 5% formic acid. The volume was reduced to 50 μL in a vacuum centrifuge before liquid chromatography (LC)--tandem mass spectrometry (MS/MS) analysis.

LC--MS/MS {#Sec10}
---------

The peptides were separated using an Ultimate 3000 nano LC system (Dionex LC-Packings, Amsterdam, Netherlands) equipped with a 20 cm × 75 μm internal diameter (i.d.) fused-silica column custom packed with 3-μm 120-Å ReproSil Pur C18 aqua (Dr. Maisch, GMBH, Ammerbuch-Entringen, Germany). After injection, the peptides were delivered into the column at a flowrate of 30 μL/min and trapped on a 5 mm × 300 μm i.d. Pepmap C18 cartridge (Dionex LC-Packings), which were then eluted by 2% buffer B (80% ACN and 0.05% formic acid in Milli-Q water) and separated at 300 nL/min in a 10%--40% buffer B gradient within 60 min. The eluting peptides were ionized at 1.7 kV in a Nanomate Triversa Chip-based nanospray source by using a Triversa LC coupler (Advion, Ithaca, NJ, USA). Intact peptide mass spectra and fragmentation spectra were acquired on a LT QFT hybrid mass spectrometer (Thermo Fisher, Bremen, Germany). The intact masses were measured at a resolution of 50,000 in the ion cyclotron resonance (ICR) cell by using a target value of 1 × 10^6^ charges. Simultaneously, following an FT prescan, the five highest peptide signals (charge states 2+ and higher) were submitted for MS/MS in the linear ion trap (3-AMU isolation width, 30 ms activation, 35% normalized activation energy, 0.25 Q-value, and 5000-count threshold. Dynamic exclusion was applied with a repeat count of 1 and an exclusion time of 30 s.

Results {#Sec11}
=======

Sulbactam potentiates doxorubicin sensitivity in breast cancer cells {#Sec12}
--------------------------------------------------------------------

To determine whether sulbactam enhances the cytotoxicity of doxorubicin, MCF-10A (normal), BT474 (ER/PR+, Her2+), MCF-7 (ER/PR+, Her2−), MDA-MB-231 (triple negative), MDA-MB-361 (ER/PR+, Her2+), MDA-MB-435 (ER/PR−, Her2+), MDA-MB-453 (triple negative), MDA-MB-468 (triple negative), and T47D (ER/PR+, Her2−) cell lines were treated for 48 h with 0, 0.1, 0.5, 1, 5, and 10 μM doxorubicin in the presence or absence of 2 mM sulbactam for 48 h. Cell viabilities were measured through the MTT assay. Doxorubicin exerted cytotoxic effects in a dose-dependent manner against all the cell lines (Fig. [1](#Fig1){ref-type="fig"}). When the cells were treated with doxorubicin alone, the viability of the MDA-MB-468 cells was \< 50% at 0.5 µM doxorubicin, the viabilities of the MCF-7, MDA-MB-361, and MDA-MB-453 cells were \< 50% at 1 μM doxorubicin, the viabilities of the BT474, MDA-MB-231, and MDA-MB-435 cells were \< 50% at 5 μM doxorubicin, and the viability of T47D cells was \< 50% until the concentration of doxorubicin reached 10 μM. Among these breast cancer cell lines, the T47D cell line exhibited low sensitivity to doxorubicin, with a IC50 value of 8.53 µM (Fig. [1](#Fig1){ref-type="fig"}i). By contrast, the MDA-MB-453 and MDA-MB-468 cells were more sensitive to doxorubicin than the T47D cells; they had lower IC~50~ values (0.69 and 0.27 μM, respectively) than the T47D cells and had the lowest viabilities at 5 and 10 μM doxorubicin (Fig. [1](#Fig1){ref-type="fig"}g, h). Next, we analyzed whether sulbactam enhanced the cytotoxicity of doxorubicin in the breast cancer cells. When the cells were treated with a combination of sulbactam and doxorubicin, the viabilities of the eight breast cancer cell lines significantly decreased (Fig. [1](#Fig1){ref-type="fig"}b--i). The IC~50~ values of doxorubicin in all the cell lines in the presence and absence of sulbactam are summarized in Table [2](#Tab2){ref-type="table"}. The IC~50~ values of doxorubicin decreased from 1.14 to 0.54 μM in the BT474 cells, from 0.69 to 0.37 μM in the MCF-7 cells, from 3.16 to 1.25 μM in the MDA-MB-231 cells, from 0.89 to 0.46 μM in the MDA-MB-361 cells, from 1.22 to 0.51 μM in the MDA-MB-435 cells, from 0.69 to 0.27 μM in the MDA-MB-453 cells, from 0.27 to 0.05 μM in the MDA-MB-468 cells, and from 8.53 to 3.83 μM in the T47D cells in the presence of sulbactam. The IC~50~ of doxorubicin in breast cancer cells treated with a combination of sulbactam and doxorubicin was less than half of the IC~50~ of doxorubicin in the breast cancer cells treated with doxorubicin alone excluding the resistance of the MCF-7 and MDA-MB-361 cells, showed 1.85- and 1.96-fold decreases, respectively. By contrast, the MCF-10A cells (breast epithelial cells), did not exhibit evident differences in cell viability in the absence and presence of sulbactam; the IC~50~ values were 2.51 and 2.50, respectively (Fig. [1](#Fig1){ref-type="fig"}a). Among all the breast cancer cell lines, sulbactam considerably increased doxorubicin sensitivity in the MDA-MB-453 and MDA-MB-468 cells, by reducing the IC~50~ of doxorubicin by 2.6- and 5.0-fold, respectively, Subsequently, the cytotoxicity of sulbactam alone was analyzed in the MCF-10A, MDA-MB-453, and MDA-MB-468 cells. The cells were treated with 0, 1, 2, 4, and 8 mM sulbactam. Sulbactam did not exhibit an evident cytotoxic effect on any of the three cell lines at concentrations of up to 8 mM (Fig. [2](#Fig2){ref-type="fig"}). However, when combined with 0.5 μM doxorubicin, sulbactam potentiated the cytotoxicity of doxorubicin without evident dose dependence in the MDA-MB-453 and MDA-MB-468 cells. Thus, sulbactam has low cytotoxicity and can enhance the sensitivity of breast cancer cells toward doxorubicin.Fig. 1Treatment with a combination of sulbactam and doxorubicin reduced the viability of breast cancer cells. **a** MCF10A, **b** BT474, **c** MCF-7, **d** MDA-MB-231, **e** MDA-MB-361, **f** MDA-MB-435, **g** MDA-MB-453, **h** MDA-MB-468, **i** T47D. Data are expressed as the percentage of cell viability compared with the negative control in which the cell viability was assumed to be 100%. Reported values represent mean ± SD of at least three independent experiments. \*p \< 0.05 and \*\*p \< 0.01 versus only Dox-treated cells. *Sul* sulbactam, *Dox* doxorubicin, *ER* estrogen receptor, *PR* progesterone receptor, *HER2* human epidermal growth factor receptor 2, *MTT* 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide, *SD* standard deviation Table 2IC~50~ and resistance fold of breast cell lines in the present of sulbactam and doxorubicinCell lineIC~50~ of Doxorubicin (Dox, μM)Resistance foldDoxDox + SulDox + Sul/DoxMCF10A2.512.501.00BT4741.140.540.47MCF-70.690.370.54MDA-MB-2313.161.250.40MDA-MB-3610.890.460.51MDA-MB-4351.220.510.42MDA-MB-4530.690.270.39MDA-MB-4680.270.050.20T47D8.533.830.45IC~50~ was calculated from the results of Fig. [1](#Fig1){ref-type="fig"} using CompuSyn. Resistance fold was determined by dividing the IC50 values of cells treated with doxorubicin and 2 mM sulbactam (Dox + Sul) by the IC50 of cells treated with doxorubicin (Dox) Fig. 2Sulbactam alone did not significantly affect cell viability of the breast cancer cell lines. **a** The MCF-10A cells treated with Sul (squares), Sul + D0.5 (triangles), and Sul + D1.0 (circles). The **b** MDA-MB-453 and **c** MDA-MB-468 cells treated with Sul (squares) and Sul + D0.5 (triangles). Data are expressed as the percentage of cell viability compared with negative control in which cell viability was assumed to be 100%. Reported values represent mean ± SD of at least three independent experiments. *Sul* sulbactam, *Dox* doxorubicin, *MTT* 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide, *SD* standard deviation

Proteomic profiling of total proteins from MDA-MB-468 cells treated with and without sulbactam in presence of doxorubicin {#Sec13}
-------------------------------------------------------------------------------------------------------------------------

The MDA-MB-468 cells were treated with or without 2 mM sulbactam in the presence of 0.1 μM doxorubicin for 24 h. The total cell lysates were harvested for LC--MS/MS analysis. In total, 2937 proteins were identified using Sequest, which were validated using Scaffold. The expression of 66 and 70 proteins were significantly upregulated and downregulated, respectively, in the MDA-MB-468 cells treated with a combination of sulbactam and doxorubicin (based on p value \< 0.05 and fold change \> 2; Tables [3](#Tab3){ref-type="table"} and [4](#Tab4){ref-type="table"}). The UniProt database was used to classify the identified proteins according to their biological processes. The upregulated proteins were classified as RNA processing, response to DNA damage, response to stress, cytoskeleton organization, protein folding, ubiquitin-dependent protein catabolic process, vesicle-mediated transport, carbohydrate metabolism, amino acid metabolism, and positive regulation of apoptosis proteins (Table [3](#Tab3){ref-type="table"}). The downregulated proteins were classified as translation, regulation of transcription, RNA processing, ABC transporter, cytoskeleton organization, protein folding, protein catabolic process, carbohydrate metabolism, mitochondrial metabolic process, negative regulation of apoptosis, and signal transduction proteins (Table [4](#Tab4){ref-type="table"}). The connections among the proteins and GO biological processes of the proteins were tested through STRING network analysis. The proteins are represented as nodes. The thickness of the edges indicates the strength of correlations between the proteins according to neighborhood, gene fusion, co-occurrence, co-expression, previous experiments, databases, and text-mining information at confidence scores higher than 0.5. As shown in Fig. [3](#Fig3){ref-type="fig"}a, 38 of the 60 proteins which were upregulated in the MDA-MB-468 cells treated with a combination of sulbactam and doxorubicin were associated with response to stimuli. Functional clusters included proteins involved in carbohydrate metabolism, tubulin-associated cytoskeleton organization, and ubiquitin-dependent protein catabolic process. As shown in Fig. [3](#Fig3){ref-type="fig"}b, 31 of 68 proteins which were downregulated in the MDA-MB-468 cells treated with a combination of sulbactam and doxorubicin were associated with gene expression. The functional clusters of these downregulated proteins were associated with actin remodeling, mitochondrial metabolic process, protein catabolic process, transcription and RNA process, and translation.Table 3List of upregulated proteins in the Dox- and Sul-treated MDA-MB-468 cellsProtein nameAbbreviationUniProt IDMass (Da)pISpectrum countDox + Sul/Doxp valueBiological processDoxDox + SulFold^a^Putative pre-mRNA-splicing factor ATP-dependent RNA helicase DHX15DHX15O4314390,932.87.10.000.82100.002.57E−07RNA processingU5 small nuclear ribonucleoprotein 200 kDa helicaseSNRNP200O75643244,507.65.70.001.10100.002.41E−02RNA processingSpliceosome RNA helicase DDX39BDDX39BQ5STU348,826.17.20.001.85100.002.52E−05RNA processingATP-dependent RNA helicase DDX3XDDX3XO0057173,112.26.70.001.39100.007.43E−04RNA processingNucleolar protein 14NOP14P7831697,668.79.10.000.96100.001.50E−03RNA processingGrowth arrest and DNA damage-inducible proteins-interacting protein 1GADD45GIP1Q8TAE825,383.99.50.001.09100.002.70E−02Response to DNA damage26S protease regulatory subunit 6APSMC3P1798049,203.55.10.271.114.064.64E−02Response to DNA damageProteasome subunit beta type-4PSMB4P2807029,204.39.10.000.96100.001.08E−03Response to DNA damageTransformation/transcription domain-associated proteinTRRAPQ9Y4A5437,601.89.10.000.55100.003.412E−05Response to DNA damageProtein DEKDEKP3565942,674.49.30.001.53100.006.37E−03Response to DNA damageSerine/threonine-protein kinase BRSK1BRSK1Q8TDC385,087.09.50.000.55100.002.57E−07Response to DNA damageAdenomatous polyposis coli proteinAPCE7EMH932,790.85.40.000.55100.003.41E−05Response to DNA damageDihydropyrimidinase-related protein 2DPYSL2Q1655562,293.65.90.000.98100.001.32E−02Response to stressSodium/potassium-transporting ATPase subunit beta-1ATP1B1P0502635,061.39.10.001.11100.007.81E−03Response to stressERO1-like protein alphaERO1LQ96HE751,991.85.40.000.56100.001.12E−04Response to stressSTE20-like serine/threonine-protein kinaseSLKQ9H2G2142,695.43.70.000.70100.002.30E−02Response to stressHeat shock-related 70 kDa protein 2HSPA2P5465270,021.05.60.002.69100.009.41E−04Response to stressPutative heat shock 70 kDa protein 7HSPA6P4874140,244.47.70.003.08100.005.50E−03Response to stressLipoprotein, Lp(A)LPAQ1HP67226,516.17.20.000.55100.002.57E−07Response to stressApolipoprotein(a)LPAP08519501,319.87.20.000.55100.002.57E−07Response to stressPeroxiredoxin-6PRDX6P3004124,903.86.00.271.686.151.42E−02Response to stressSolute carrier family 12 member 2SLC12A2P55011131,447.16.00.372.216.034.53E−03Response to stressThioredoxin-related transmembrane protein 1TMX1Q9H3N131,791.33.70.000.83100.002.70E−04Response to stressTransmembrane protein 109TMEM109Q9BVC626,210.111.20.000.56100.002.70E−04Response to stressMICOS complex subunit MIC60IMMTQ1689180,026.55.71.122.742.451.34E−04Response to stressSignal transducer and activator of transcriptionSTAT1J3KPM983,360.67.20.000.83100.002.70E−04Response to stresscDNA FLJ78587TUBA1BA8JZY950,135.75.44.8014.973.125.22E−03Cytoskeleton organizationMyosin regulatory light chain 12AMYL12AP1910519,794.14.71.235.814.713.07E−02Cytoskeleton organizationMyosin regulatory light chain 12BMYL12BO1495019,779.24.71.235.814.713.07E−02Cytoskeleton organizationActin-like protein 8ACTL8Q9H56841,360.47.20.271.114.064.64E−02Cytoskeleton organizationPlastin-1PLS1Q1465170,253.65.40.000.97100.007.05E−03Cytoskeleton organizationF-actin-capping protein subunit betaCAPZBP4775631,219.35.40.002.46100.004.59E−02Cytoskeleton organizationVimentinVIMB0YJC526,858.93.70.000.69100.002.03E−02Cytoskeleton organizationFilamin AFLNAQ60FE5278,226.97.22.517.533.012.05E−02Cytoskeleton organizationTubulin-folding cofactor BTBCBQ9942627,325.58.70.000.70100.002.30E−02Cytoskeleton organizationTubulin beta-3 chainTUBB3Q1350950,432.74.81.416.704.753.23E−02Cytoskeleton organizationTubulin beta-4A chainTUBB4AP0435049,585.84.80.001.94100.002.70E−04Cytoskeleton organizationKinesin heavy chain isoform 5CKIF5CO60282109,494.85.90.001.10100.003.85E−02Cytoskeleton organizationSeptin-9SEPTIN9Q9UHD865,401.69.50.001.40100.001.64E−02Cytoskeleton organizationLaminin subunit alpha-2LAMA2A0A087WYF1343,419.07.20.281.264.464.32E−02Cytoskeleton organizationMalectinMLECQ1416532,233.97.20.000.70100.002.15E−02Protein foldingT-complex protein 1 subunit gammaCCT3Q2TU6460,579.17.20.003.62100.001.49E−02Protein foldingVesicle-associated membrane protein-associated protein B/CVAPBE5RK647801.09.50.001.54100.003.83E−02Protein foldingPEST proteolytic signal-containing nuclear proteinPCNPQ8WW1218,924.96.90.281.916.952.46E−02Ubiquitin-dependent protein catabolic processNEDD8-conjugating enzyme Ubc12UBE2 MP6108120,900.09.10.000.83100.002.70E−04Ubiquitin-dependent protein catabolic processCullin-3CUL3A0A087WTG339,147.29.50.001.94100.002.70E−04Ubiquitin-dependent protein catabolic processCoatomer subunit betaCOPB1P53618107,142.67.20.001.10100.003.02E−02Vesicle-mediated transportEndoplasmic reticulum resident protein 29ERP29F8VY0218,115.99.10.000.55100.003.41E−05Vesicle-mediated transportKinesin-like protein KIF16BKIF16BQ96L93152,011.77.20.001.12100.003.33E−02Vesicle-mediated transportPhosphatidylinositol *N*-acetylglucosaminyltransferase subunit APIGAP3728754,126.79.100.55100.002.574E−07Vesicle-mediated transportRas-related protein Rab-35RAB35Q1528623,025.39.10.000.98100.008.01E−03Vesicle-mediated transportRas-related protein Rab-15RAB15P5919024,390.65.50.000.98100.008.01E−03Vesicle-mediated transportRas-related protein Rab-15 isoform AN2RAB15G5ELZ513,781.89.10.000.98100.008.01E−03Vesicle-mediated transportRas-related protein Rab-15 isoform AN3RAB15G5ELZ612,759.79.10.000.98100.008.01E−03Vesicle-mediated transportEnolaseENO1F5H0C834,762.33.60.000.83100.002.70E−04Carbohydrate metabolismPhosphoglycerate mutasePGAM1A4D2J628,219.69.50.001.40100.002.15E−02Carbohydrate metabolismATP-dependent 6-phosphofructokinase, platelet typePFKPB1APP822,939.39.10.000.56100.001.12E−04Carbohydrate metabolismGamma-enolaseENO2P0910447,268.64.90.000.83100.002.70E−04Carbohydrate metabolismTransaldolaseTALDO1F2Z39335,328.99.50.002.75100.003.85E−02Carbohydrate metabolismGanglioside-induced differentiation-associated protein 1GDAP1Q8TB3641,345.89.10.000.56100.002.70E−04Amino acid metabolic processMultifunctional methyltransferase subunit TRM112-like proteinTRMT112F5GX7711,972.07.80.000.56100.001.12E−04Amino acid metabolic processGCSH proteinGCSHQ6IAT219,025.83.70.000.96100.008.84E−03Amino acid metabolic processElongation factor 1-alpha 2EEF1A2Q0563950,470.29.10.003.21100.001.94E−02Positive regulation of apoptotic processApoptotic chromatin condensation inducer in the nucleusACIN1Q9UKV3151,861.95.40.000.82100.001.30E−02Positive regulation of apoptotic process*Sul* sulbactam, *Dox* doxorubicin^a^The fold is from Dox + Sul/Dox, if the number of Dox is 0.00, the fold would be shown as 100.00 Table 4List of downregulated proteins in the Dox- and Sul-treated MDA-MB-468 cellsProtein nameAbbreviationUniProt IDMass (Da)pISpectrum countDox + sul/Doxp valueBiological processDoxDox + SulFold^a^60S ribosomal protein L4RPL4P3657847,566.111.14.531.96− 2.312.25E−02Translation60S ribosomal protein L17RPL17J3QLC820,246.89.51.840.27− 6.764.24E−02Translation60S ribosomal protein L24RPL24C9JXB814,368.811.30.560.00− 100.001.30E−04Translation60S ribosomal protein L27aRPL27AP4677616,430.211.03.201.47− 2.171.42E−02Translation60S ribosomal protein L37aRPL37AP6151310,275.39.51.390.00− 100.004.08E−03Translation40S ribosomal protein S3aRPS3AD6RAT025,887.19.57.510.00− 100.004.01E−03TranslationEukaryotic translation initiation factor 1A, Y-chromosomalEIF1AYO1460216,442.44.60.650.00− 100.001.43E−03TranslationEukaryotic translation initiation factor 1A, X-chromosomalEIF1AXP4781316,460.44.60.650.00− 100.001.43E−03TranslationEukaryotic translation initiation factor 4 gamma 1EIF4G1B2RU10176,207.35.41.120.00− 100.003.18E−02TranslationEukaryotic translation initiation factor 3 subunit JEIF3 JO7582229,062.43.71.380.27− 5.101.16E−02TranslationEukaryotic translation initiation factor 6EIF6P5653726,599.23.70.700.00− 100.002.17E−02TranslationNascent polypeptide-associated complex subunit alphaNANA2Q1376523,383.94.51.570.00− 100.001.47E−03TranslationNascent polypeptide-associated complex subunit alpha, muscle-specific formNANAF8VZJ215,016.04.91.570.00− 100.001.47E−03TranslationEukaryotic translation elongation factor 1 beta 2EEF1B2A4D1M624,891.03.71.260.00− 100.007.44E−03TranslationHeterogeneous nuclear ribonucleoprotein D0HNRNPDQ1410338,434.27.64.252.39− 1.782.07E−02TranslationMAP kinase-interacting serine/threonine-protein kinase 1MKNK1E9PMF112,586.39.50.840.00− 100.008.80E−07TranslationHeterogeneous nuclear ribonucleoproteins C1/C2HNPNPCG3V2Q133,570.95.03.500.81− 4.302.30E−02TranslationKH domain-containing, RNA-binding, signal transduction-associated protein 1KHDRBS1Q0766648,227.38.70.970.00− 100.001.21E−02Regulation of transcriptionHigh mobility group protein HMG-I/HMG-YHMGA1P1709611,544.810.31.530.70− 2.192.87E−02Regulation of transcriptioncDNA FLJ54188, moderately similar to High mobility group protein HMG-I/HMG-YHMGA1B4DWA034,301.410.41.530.70− 2.192.87E−02Regulation of transcriptionSerrate RNA effector molecule homologSRRTQ9BXP5100,666.77.20.970.00− 100.007.88E−03Regulation of transcriptionProtein SIX6OS1C14orf39Q8N1H768,166.05.40.560.00− 100.001.30E−04Regulation of transcriptionHeterogeneous nuclear ribonucleoprotein D-likeHNRPDLO1497946,437.59.62.230.00− 100.009.63E−03Regulation of transcriptionZinc finger and BTB domain-containing protein 14ZFP161O4382950,956.55.40.740.00− 100.009.26E−03Regulation of transcriptionGolgin-45BLZF1Q9H2G944,910.49.10.700.00− 100.001.68E−02Regulation of transcriptionZinc finger protein neuro-d4DPF1E9PDV345,285.67.20.560.00− 100.001.30E−04Regulation of transcriptionHistone cluster 1, H1eHIST1H1EQ4VB2421,893.39.54.440.00− 100.001.25E−02Regulation of transcriptionSerine/arginine-rich splicing factor 10SRSF10O7549431,300.511.20.560.00− 100.001.30E−04RNA processingHeterogeneous nuclear ribonucleoprotein QSYNCRIPO6050669,471.48.75.981.95− 3.073.52E−02RNA processingTransformer-2 protein homolog alphaTRA2AQ1359532,688.611.21.110.18− 6.023.23E−02RNA processingMultidrug resistance protein 1ABCB1P08183141,479.19.13.470.84− 4.135.08E−04TransportersATP-binding cassette sub-family G member 2ABCG2Q9UNQ072,314.08.91.660.36− 4.561.05E−03TransportersATP-binding cassette sub-family A member 8ABCA8O94911179,245.99.10.560.00− 100.008.80E−07TransportersSodium/potassium-transporting ATPase subunit alpha-4ATP1A4E9PRA557,244.49.10.560.00− 100.001.30E−04TransportersSyntaxin-8STX8Q9UNK026,906.83.70.560.00− 100.008.80E−07TransportersWiskott-Aldrich syndrome protein family member 1WASF1Q9255861,652.45.40.560.00− 100.001.30E−04Cytoskeleton organizationActin-related protein 2/3 complex subunit 2ARPC2O1514434,333.19.11.230.00− 100.005.68E−03Cytoskeleton organizationActin-related protein 2/3 complex subunit 3ARPC3O1514520,415.58.80.970.00− 100.007.88E−03Cytoskeleton organizationRas GTPase-activating-like protein IQGAP1IQGAP1P46940189,120.86.11.250.00− 100.004.32E−04Cytoskeleton organizationMyosin light chain 6BMYL6BP1464922764.16.32.230.00− 100.008.80E−07Cytoskeleton organizationTBC1 domain family member 31WDR67Q96DN5124189.89.11.110.00− 100.009.75E−04Cytoskeleton organizationPrelamin-A/CLMNAQ5TCI855762.46.610.730.28− 37.731.74E−02Cytoskeleton organizationLamin A/CLMNAW8QEH365116.99.111.690.00− 100.008.86E−03Cytoskeleton organizationCalumeninCALUO4385234961.14.51.660.36− 4.602.73E−02Cytoskeleton organizationLamina-associated polypeptide 2, isoforms beta/gammaTMPOP4216750670.39.51.850.74− 2.492.75E−02Cytoskeleton organizationKinesin-like proteinKIF15A0A087X0P0312105.25.52.190.00− 100.006.76E−06Cytoskeleton organizationDnaJ homolog subfamily A member 1DNAJA1P3168944868.47.21.260.36− 3.442.12E−02Protein foldingT-complex protein 1 subunit epsilonCCT5P4864359539.85.43.470.41− 8.399.26E−03Protein foldingT-complex protein 1 subunit betaCCT2P7837157357.06.01.110.00− 100.001.30E−04Protein foldingCysteine and histidine-rich domain-containing protein 1CHORDC1Q9UHD137489.97.20.550.00− 100.006.76E−06Protein foldingCDC37 proteinCDC37Q6FG5944453.53.71.780.41− 4.384.29E−02Protein folding26S proteasome non-ATPase regulatory subunit 7PSMD7P5166537025.46.30.690.00− 100.001.95E−02Protein catabolic processProteasome subunit beta type-3PSMB3P4972022949.09.10.560.00− 100.001.30E−04Protein catabolic processProteasome subunit alpha type-4PSMA4P2578929483.87.60.650.00− 100.001.01E−03Protein catabolic processUbiquitin carboxyl-terminal hydrolase 43USP43Q70EL4122809.59.50.830.00− 100.004.42E−02Protein catabolic processEnolase-like protein ENO4ENO4J3KNX168464.96.31.110.00− 100.005.54E−03Carbohydrate metabolismPCK2 proteinPCK2Q6IB9170697.27.20.700.00− 100.002.17E−02Carbohydrate metabolismFructose-bisphosphate aldolaseALDOCA8MVZ936295.37.61.530.00− 100.002.78E−03Carbohydrate metabolismCytochrome c oxidase subunit 5A, mitochondrialCOX5AH3BNX817234.97.21.240.00− 100.004.42E−02Mitochondrial metabolic processCytochrome b5 type BCYB5BJ3KNF816694.66.30.820.00− 100.004.69E−02Mitochondrial metabolic processCytochrome b-c1 complex subunit 1, mitochondrialUQCRC1P3193052646.07.20.560.00− 100.001.30E−04Mitochondrial metabolic processMICOS complex subunit MIC19CHCHD3Q9NX6326152.49.10.700.00− 100.001.68E−02Mitochondrial metabolic processPhosphoenolpyruvate carboxykinase \[GTP\], mitochondrialPCK2Q1682270730.27.20.700.00− 100.002.17E−02Mitochondrial metabolic processDihydrolipoyllysine-residue succinyltransferase component of 2-oxoglutarate dehydrogenase complex, mitochondrialDLSTP3695748755.59.50.560.00− 100.001.30E−04Mitochondrial metabolic processPyruvate dehydrogenase E1 component subunit alpha, somatic form, mitochondrialPDHA1P0855943295.89.10.560.00− 100.001.30E−04Mitochondrial metabolic processApoptosis inhibitor 5API5Q9BZZ559004.79.11.210.27− 4.444.79E−02Negative regulation of apoptotic processEpidermal growth factor receptorEGFRA9CB80132022.76.26.030.54− 11.125.65E−03Signal transductionA-kinase anchor protein 9AKAP9Q99996453668.73.70.840.00− 100.007.75E−05Signal transductionRho GDP-dissociation inhibitor 1ARHGDIAJ3KS609944.04.20.650.00− 100.005.33E−03Signal transductionSerine/threonine-protein phosphatase PP1-alpha catalytic subunitPPP1CAP6213637512.27.21.810.00− 100.004.26E−03Signal transduction*Sul* sulbactam, *Dox* doxorubicin^a^The fold is from Dox/Dox + Sul, and "−" means the expression of protein was decrease in Dox + Sul group. If the number of Dox + Sul is 0.00, the fold would be shown as − 100.00 Fig. 3Differentially expressed proteins in the MDA-MB-468 cells in the presence of sulbactam and doxorubicin. Proteins are represented as nodes. **a** Upregulated proteins in the Dox/Sul-treated MDA-MB-468 cells. Red nodes indicate proteins that are related to the response to stimulus. **b** Downregulated proteins in the Dox/Sul-treated MDA-MB-468 cells. Red nodes indicate the proteins that are related to gene expression. *Sul* sulbactam, *Dox* doxorubicin

Sulbactam downregulates mRNA levels of ABC transporters in breast cancer cell lines {#Sec14}
-----------------------------------------------------------------------------------

Sulbactam significantly reduced ABC transporter protein expression in *A. baumannii* ATCC 19606. Breast cancer cells can actively remove doxorubicin from inside the cells by using ABC transporters to protect the cells from being killed by doxorubicin. LC--MS/MS results showed a reduction in the protein levels of ABCA8, ABCB1, and ABCG2; hence, we examined whether sulbactam can inhibit the mRNA expression of ABC transporters in the human breast cancer cells in the presence of doxorubicin. Two breast cancer cell lines, MDA-MB-453 and MDA-MB-468, were treated with 0.1 μM doxorubicin and 2 mM sulbactam for 24 h. The mRNA expression of the ABC transporters in these two cell lines were measured using real-time RT-PCR. In the presence of doxorubicin, sulbactam significantly reduced the mRNA expression of ABCB1, ABCB5, and ABCG2 by approximately 50% in the MDA-MB-453 and MDA-MB-468 cells (Fig. [4](#Fig4){ref-type="fig"}). Sulbactam also moderately reduced the mRNA expression of ABCB8, ABCB10, ABCC1, ABCC2, ABCC3, ABCC4, and ABCC5 in the MDA-MB-453 cells and those of ABCB8, ABCB10, ABCC2, ABCC5, and ABCC10 in the MDA-MB-468 cells by 20--30%. These results indicate that sulbactam downregulated the mRNA expression of several ABC transporters, particularly ABCB1, ABCB5, and ABCG2. These results also demonstrate that the combination of sulbactam and doxorubicin enhanced the sensitivity of the cells to doxorubicin by downregulating the expressions of ABC transporters related to the efflux of doxorubicin.Fig. 4Co-treatment of sulbactam and doxorubicin downregulated mRNA expression levels of ABC transporters. **a** MDA-MB-453 and **b** MDA-MB-468. The relative mRNA expression levels are expressed as compared with Dox-treated cells where the mRNA expression levels were assumed to be 1. Reported values represent mean ± SD of at least three independent experiments, each performed in triplicate. \*p \< 0.05 and \*\*p \< 0.01 versus only Dox-treated cells. *Sul* sulbactam, *Dox* doxorubicin, *SD* standard deviation

Sulbactam prolongs doxorubicin retention in breast cancer cells {#Sec15}
---------------------------------------------------------------

To investigate whether the sulbactam-induced reduction in the expression of ABC transporters inhibits the efflux of doxorubicin, the distribution of doxorubicin in breast cancer cells was observed using a confocal microscope. A time-course study was performed in the presence and absence of sulbactam. For comparison, the cells were also pretreated with verapamil, a well-known inhibitor of ABCB1 and ABCG2. The fluorescent signal corresponding to doxorubicin was primarily observed in nuclei of the cells, and the concentration of doxorubicin decreased time-dependently (Fig. [5](#Fig5){ref-type="fig"}). Pretreatment with sulbactam increased the doxorubicin concentration in the cell nuclei by 15, 45, and 74% in the MDA-MB-453 cells and 17, 26, and 44% in the MDA-MB-468 cells at 8, 12, and 16 h, respectively, compared with that in cells without sulbactam treatment. The intensities of doxorubicin were comparable between the sulbactam- and verapamil-treated MDA-MB-453 cells. Doxorubicin concentration was higher in the sulbactam-treated MDA-MB-468 cells than in the verapamil-treated cells. These results indicate that sulbactam inhibited the efflux of doxorubicin, thus prolonging doxorubicin retention in the breast cancer cells. The increase in intracellular doxorubicin levels resulted in an increase in its cytotoxicity in the breast cancer cells.Fig. 5Prolonged doxorubicin retention in breast cancer cells in the presence of sulbactam. The distribution of Dox in the **a** MDA-MB-453 and **c** MDA-MB-468 cells was observed. Dox is shown in red and DAPI in blue, which counterstained the nuclei. Scale bars, 20 μm. **b**, **d** are quantifications of **a**, **c**, respectively. Reported values indicate the means of fluorescence intensity of Dox overlapping with DAPI and are represented as mean ± SD. \*\*p \< 0.01 versus only Dox-treated cells. *Sul* sulbactam, *Dox* doxorubicin, *SD* standard deviation, *Vera* verapamil, *DAPI* (4′,6-diamidino-2-phenylindole)

Discussion {#Sec16}
==========

The coadministration of sulbactam and a β-lactam antibiotic, such as ampicillin, is an effective therapy against bacteria, such as *A. baumannii* \[[@CR42]\]. Sulbactam alone has intrinsic bactericidal effects against multidrug-resistant *A. baumannii* because it inhibits the expression of the ABC transporters as well as that of 30S and 50S ribosomal subunit proteins \[[@CR38]\]. However, the effects of sulbactam have not been explored in mammalian cells, thus far. Our study results suggest that sulbactam enhanced the cytotoxicity of doxorubicin in many of the tested breast cancer cell lines. Because of the high heterogeneity of breast cancer, we classified breast cancer cell lines as hormone-receptor-positive cancer, HER2-positive cancer, and TNBC; the cells were then treated with sulbactam and doxorubicin. All the cell lines responded to doxorubicin and sulbactam---a finding is evidently uncorrelated with the characteristic of these cell lines. Thus, a combination of doxorubicin and sulbactam exhibited the most significant cytotoxicity in the MDA-MB-453 and MDA-MB-468 cells. Dose-dependency tests showed that approximately 1--8 mM sulbactam was not cytotoxic to MDA-MB-453, MDA-MB-468, and MCF10A cells, which are typically used as normal breast cell lines; hence, in combination with doxorubicin, sulbactam exerted a synergistic effect on doxorubicin.

The results of LC--MS/MS indicated that most of the upregulated proteins (21/66) associated with stress and DNA damage response, such as heat shock-related 70-kDa protein 2 and adenomatous polyposis coli protein, may respond to the stress caused by sulbactam. When used as a drug, sulbactam also stimulates some metabolic pathways and cytoskeleton organizations, such as carbohydrate metabolism and tubulin-associated cytoskeleton organization. In the presence of doxorubicin and sulbactam evidently inhibited the initiation of RNA processing, transcription, and translation (Fig. [6](#Fig6){ref-type="fig"}). Doxorubicin interacts with DNA through intercalation between bases and macromolecular biosynthesis inhibition \[[@CR19]\]. This inhibits the progression of topoisomerase II, which relaxes supercoils in DNA during transcription. Through intercalation, doxorubicin can also induce histone eviction from transcriptionally active chromatin \[[@CR43]\]. Consequently, here, RNA processing and translation were downregulated in the doxorubicin-exposed cells. Sulbactam increased the doxorubicin retention time in the breast cancer cells. Therefore, in the presence of sulbactam, the effects of doxorubicin on transcription and translation were enhanced, and the 60S ribosomal proteins, namely L4, L17, L24, L37a, and 40S ribosomal protein 3A, and translation initiation-associated proteins, namely eIF1A, eIF3, eIF4G1, eIF6, and eEF1B, were downregulated. Hence, the initiation of the translation pathway was inhibited (Fig. [6](#Fig6){ref-type="fig"}). The results of LC--MS/MS also indicated that the expression of ABC transporter proteins ABCA8, ABCB1, and ABCG2 were downregulated, corresponding to our previous finding that sulbactam inhibits ABC transporters of *A. baumannii* and thus kills the bacterium \[[@CR38]\]. Most ABC transporter families are transmembrane proteins, which are difficult to isolate and identify through total protein LC--MS/MS; hence, we used real-time RT-PCR to determine the effects of sulbactam on the mRNA expression of the ABC transporter proteins. The expression of ABC transporter proteins in breast cancer cells is highly heterogeneous \[[@CR33], [@CR44]\]; thus, we selected the ABCB superfamily, the ABCC superfamily, and ABCG2, which are strongly associated with drug resistance in breast cancer cells \[[@CR23], [@CR26], [@CR32]\]. Based on the results of other studies and our PCR analysis, we selected ABCB1, ABCB2, ABCB8, ABCB10, ABCC1, ABCC2, ABCC3, ABCC4, ABCC5, ABCC10, and ABCG2, which exhibit high mRNA expression levels for precise real-time RT-PCR analysis.Fig. 6Co-treatment of sulbactam and doxorubicin blocked the initiation of translation in breast cancer cells. The illustration shows that treatment of the MDA-MB-468 cells with Sul (blue circles) and Dox (red circles) reduced the protein expression levels of eIF1A, eIF3, eIF4G1/3, eIF6, small 40S subunit, and large 60S subunit in the cells. Therefore, the transcription and initiation of translation pathways were blocked. *Sul* sulbactam, *Dox* doxorubicin

Although the effects of sulbactam on these ABC transporters were different in MDA-MB-453 and MDA-MB-468 cells, we conclude that in the presence of sulbactam and doxorubicin, the mRNAs levels of the indicated ABC transporter proteins were evidently downregulated. ABCB1, ABCB5, ABCB8, ABCC1, ABCC2, ABCC3, and ABCG2 \[[@CR22], [@CR45]--[@CR48]\] were considered to confer resistance to doxorubicin on the breast cancer cells. We further found that ABCB10, ABCC4, and ABCC5 in the MDA-MB-453 cells and ABCB10, ABCC5, and ABCC10 in the MDA-MB-468 cells also responded to sulbactam treatment. Studies have reported that ABCB5, ABCB8, ABCB10, ABCC2--5, and ABCC10 are overexpressed in breast cancer cells or are associated with breast cancer progression \[[@CR44], [@CR49]--[@CR53]\]. Our doxorubicin efflux assay also indicated that in the presence of sulbactam, the retention time of doxorubicin in MDA-MB-453 and MDA-MB-468 cells was prolonged significantly. We used the computer simulation and found that sulbactam may compete with ATP for the ATP-docking sites of ABCB1, ABCB10, ABCC1, and MsbA, which exhibit structures similar to the ABCG2 (data not shown). This result provides a possibility how sulbactam inhibits the expression and function of ABC transporters, and this possibility is worthy to do more experiments to confirm it.

Conclusion {#Sec17}
==========

In conclusion, this is the first study that using sulbactam in the mammalian cell. The combination of sulbactam and doxorubicin can enhance the cytotoxicity of doxorubicin in the breast cancer cells by inhibiting the transcription and initiation of translation associated proteins and ABC transporters, reducing their expression, and blocking the efflux of doxorubicin, thus triggering apoptosis in the breast cancer cells. From these results, sulbactam can be used in breast cancer treatment which can decrease the prescribed dose of doxorubicin to avoid the adverse effects.
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